GnRH Immunogenic Analog for Ferret Adrenocortical Disease

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Adrenocortical disease (ACD) in ferrets, characterized by adrenal gland hyperplasia and excessive steroid hormone production, is prevalent in neutered ferrets and can lead to severe clinical symptoms and potentially fatal outcomes, with existing treatments providing only temporary relief.

Innovation Solution

Administration of gonadotropin-releasing hormone (GnRH) or GnRH immunogenic analogs conjugated to a carrier protein, which suppresses luteinizing hormone secretion, reducing adrenal hyperplasia and steroid hormone production, and providing long-term relief from ACD symptoms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If GnRH analogs are administered to suppress LH secretion and treat ACD, then the duration of relief is extended to a year or more, but the device complexity increases due to the need for carrier protein conjugation and immunogenic analog development

Engineering Contradiction:

Improveduration of relief from ACDVSAvoidcomplexity of GnRH analog formulation

Core Design Contradiction:

Duration of action of moving objectVSDevice complexity

Solution Approach 1:

The patent applies preliminary action by pre-conjugating GnRH analogs to carrier proteins before administration. This pre-preparation of immunogenic analogs enables long-term suppression of LH secretion and ACD symptoms for a year or more, as the conjugated forms stimulate prolonged immune response and antibody production that continuously blocks GnRH receptors.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses composite materials by combining GnRH analogs with carrier proteins to create conjugated immunogenic analogs. This composite formulation enhances the duration of action significantly, providing extended control over ACD symptoms while maintaining the biological activity of the GnRH analog through the carrier protein conjugation.

Inventive Principle:

Principle #40Composite materials

2Reliability

If GnRH analogs are administered to provide long-term relief from ACD, then the reliability of treatment is improved, but the ease of operation decreases due to the complexity of administration protocols

Engineering Contradiction:

Improvereliability of ACD treatmentVSAvoidease of treatment administration

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent applies self-service by utilizing the ferret's own immune system to produce antibodies against GnRH. The conjugated GnRH analogs stimulate the ferret's immune system to generate anti-GnRH antibodies, which then continuously block GnRH receptors and suppress LH secretion. This self-generated immune response provides reliable long-term treatment without requiring external intervention or complex monitoring protocols.

Inventive Principle:

Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Significantly reduces the incidence and severity of ACD in ferrets for a period of a year or more with a single dose, offering extended control over the clinical symptoms and hormone imbalances associated with the disease.

Implementation Method 1

Down regulation of GnRH receptors and subsequent suppression of the production and release of these gonadotropins have been shown to reduce specific hormone production and eliminate hormone effects in ferrets

Methodology Applied

Scientific EffectDownregulation of GnRH receptors:

Implementation Method 2

GnRH or GnRH immunogenic analogs which are conjugated to a carrier protein... Administration of the GnRH or GnRH immunogenic analog significantly reduces the concentration of luteinizing hormone in the serum of a treated ferret

Methodology Applied

Scientific EffectImmune response to GnRH analogs:

Data Source

PatentUS8927495B1Use of GnRH and analogs thereof for the prevention and treatment of pet ferret adrenocortical hyperplasia

Publication Date: 2015.01.06 THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

AI summary

Adrenocortical disease (ACD) in ferrets develops as a result of the effect of increased concentration of Luteinizing Hormone (LH) on adrenal LH receptors. This increase in LH often results from the neutering of male or female ferrets. Neutered ferrets have no negative feedback of the ovarian or testicular hormone and as a result LH is elevated 3 to 10 times normal. Elevated LH may be prevented and/or treated by injection of GnRH vaccine. Administration of GnRH produces antibodies to endogenous GnRH. The GnRH-anti-GnRH immune-complex is ineffective in stimulating the release of LH and FSH in the anterior pituitary resulting drop in concentration of LH in the systemic circulation. This reduction in LH significantly reduces the occurrence or clinical symptoms of ACD therein. Moreover, treatment of ferrets with the GnRH provides long term relief from ACD for a period of a year or more.